Specialty Pharmacy

Mathematicians at Cornell University are using game theory to model how cancer treatment may be administered more sparingly with maximized effect.

The findings are part of the I-SPY clinical trial and were presented at the American Association for Cancer Research virtual annual meeting.

Although lifesaving drugs became available around 1998 to treat hepatitis C, they were expensive, which limited access for some patients.

Gregory Leighton, RPh, vice president of clinical solutions and patient access for Asembia, discusses how health care technology can be leveraged for the benefit of individual patients.

The objective of the study was to examine whether positive treatment effects in cancer randomized clinical trials apply to specific demographic or insurance subgroups.

A recent study presented a risk prediction model that effectively combined genetic and clinical factors with circulating biomarkers to identify people with a higher than normal risk of pancreatic cancer.

New research has discovered new elements to immunotherapy drugs that target programmed death-ligand 1 on the surface of cancer cells.

There are few effective treatment options for patients with HER2-positive breast cancer who have received 2 or more previous therapies for advanced disease, according to the study authors.

Gregory Leighton, RPh, vice president of clinical solutions and patient access for Asembia, addresses how the specialty pharmacy model can be applied to the retail channel.

The results of the ongoing trial were presented at the 2020 American Association for Cancer Research Virtual Annual Meeting I.

Previously, the only women with ovarian cancer eligible to be treated with PARP inhibitors as monotherapy in the maintenance setting were those with a BRCA mutation.

According to new research, biomarkers that signal whether a patient's cancer treatment may be harming their heart have been identified.

Researchers have discovered a natural protective mechanism that leads to the programmed death of potentially diseased cancer cells.

Shivani Patel, RPh, SVP, Clinical Operations and Technology, Asembia, discusses its reach in specialty pharmacy, and the company's growth.

In a lecture at the virtual Community Oncology Conference 2020, Christine Roussel discussed some clinical considerations for the use of medical cannabis in patients with cancer.

Research confirms earlier studies that found talazoparib improved patient-reported quality-of-life measures and had a tolerable safety profile.

The additional dosage is approved across all adult indications, including monotherapy and combination therapy, according to Merck.

Gregory Leighton, RPh, vice president of clinical solutions and patient access for Asembia, discusses how technology solutions can enhance collaborative care for specialty pharmacists.

A study recently investigated uterine serous carcinoma in order to more quickly identify those patients with an advanced form of the disease and find the appropriate treatment method for them.

There are a variety of interventions that can be used to improve survival after a patient reports cancer toxicity following treatment.

Individuals with the progressive condition often struggle to control their motor fluctuations.

Thom Cohn, chief strategy officer, Asembia, discusses recent developments in specialty pharmacy models.

An expert panel at the Community Oncology Conference 2020 discussed how COVID-19 is changing the future of community oncology.

Alexander Spira, MD, PhD, FACP, discussed how there are many types of malignancies when it comes to lung cancer, and we need to set this paradigm for our patients in the future.

The Alliance for Pharmacy Compounding created the tool to help address a need for drugs to treat patients with COVID-19.

According to the results of a nationwide survey conducted among clinical pharmacists, too many working hours is the major factor causing burnout, followed by inadequate management.

The current state of oncology is shaping challenges for the future specifically in the areas of telehealth, home infusions, and a surge of new patients that have not been to oncology clinics yet.

Experts discuss what their teams have learned throughout the COVID-19 pandemic, during the COA virtual conference.